适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Eyed Pharma
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participantsClostridioides difficile (C. difficile)MedDRA version: 20.0Level: PTClassification code: 10054236Term: Clostridium difficile infection Class: 100000004862CTIS2023-506407-26-00Idorsia Pharmaceuticals Ltd.125
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
进行中（未招募）
1 期
A randomised, open-label, reference-replicated crossover trial to investigate the bioequivalence of two formulations of Silexan 80 mg in healthy volunteersCTIS2023-503647-34-00Dr. Willmar Schwabe GmbH & Co. KG92
进行中（未招募）
1 期
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomasarge Granular Lymphocytic Leukemia or Cytotoxic LymphomasMedDRA version: 20.0Level: LLTClassification code: 10029430Term: NK-cell leukemia Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065862Term: T-cell large granular lymphocytic leukemia Class: 10029104CTIS2023-503550-13-00Dren Bio Inc.116
进行中（未招募）
1 期
MK-1403 Single Dose Formulation PK StudyMedDRA version: 20.0Level: LLTClassification code: 10003601Term: Atherosclerosis Class: 10047065AtherosclerosisCTIS2023-507984-20-00Merck Sharp & Dohme LLC16